What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

The POC testing market is set to reach $49 billion by 2018.

What if you could identify high risk patients at the earliest stage of their cardiovascular disease?

Worldwide we are the number one laboratory in measuring Matrix Gla Protein (MGP).

VitaK has a substantial investment program to increase its own clinical equipment for in-house clinical endpoint measurements in human intervention trials and clinical trials.

VitaK Innovation in Life Science has a strong focus on the development of new Point of Care and In Vitro Diagnostic tests.

Both fundamental and applied research are the core business of VitaK. We offer our expertise in the form of contract research for third parties.

VitaK has its own facilities for blood sampling and measuring clinical endpoints in the various human intervention trials that are executed.

The POC testing market is set to reach $49 billion by 2018.

VitaK Contactform

6 + 2 =

Vitak

VitaK Innovation in Life Science
Oxfordlaan 55
6229 EV Maastricht
The Netherlands

Head office:
Oxfordlaan 55
6229 EV Maastricht
The Netherlands
T: +31 (0)43 388 5926

Laboratories:
Oxfordlaan 70
6229 EV Maastricht
The Netherlands
E: info@vitak.com